Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprilimab for Recurrent/Residual Nasopharyngeal Carcinoma
NCT04534855Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04534855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534855.